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The sunshine vitamin has been associated with reduced risk for many chronic illnesses including cancer
and cancer mortality. Epidemiologic and ecological studies have suggested that living at higher latitudes
and having lower blood levels of 25-hydroxyvitamin D are associated with increased risk for up to 15
cancers including breast, colon, lung, lymphoma, pancreatic, ovarian and prostate cancer. Most ran-
domized controlled trials using appropriate doses of vitamin D have suggested that improvement in
vitamin D status reduces risk for several cancers. Although the exact mechanism by which enhanced
vitamin D status reduces risk for cancer is not completely understood, there is evidence that by raising
blood levels of 25-hydroxyvitamin D this metabolite can enter a wide variety of cells in the body and
then be converted to 1,25-dihydroxyvitamin D3. The vitamin D metabolite, 1,25-dihydroxyvitamin D3, has
been demonstrated to markedly reduce cellular proliferation especially of malignant cells that have a
vitamin D receptor. It also induces terminal differentiation. 1,25-dihydroxyvitamin D3 is also anti-
angiogenic and pro-apoptotic which also plays a role in reducing the growth and spread of malignant
cells. Thus improvement in vitamin D status with sensible sun exposure, vitamin D supplementation and
ingesting foods containing vitamin D is a reasonable strategy to reduce risk of malignancy.
 2014 The Author. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
For more than a decade research has suggested that there may
be an association with sun exposure, vitamin D status and risk for
developing a variety of some of themost common cancers. A variety
of basic and clinical research activities have provided insights as to
how the sunshine vitamin may play a role in reducing risk for
deadly cancers including breast and colon cancers. The goal of this
review is to give a broad overview of studies and mechanisms
related to vitamin D and cancer.Physiology and metabolism of vitamin D
There are two sources of vitamin D and two major forms of
vitamin D. During sun exposure the precursor of cholesterol, 7-
dehydrocholesterol, in the epidermis and dermis absorbs solar ul-
traviolet B radiation (290e315 nm) and is converted to previtamin
D3 [1]. Once formed previtamin D3 undergoes a rearrangement of
its double bonds to form vitamin D3 which then exits the plasma
membrane of the skin cells into the extravascular space. It diffusesBY-NC-ND license (http://
nc. Open access under CC BY-NC-ND liceninto the dermal capillary bed for transport to the liver [2,3] (Fig. 1).
Vitamin D3 is also present in oily ﬁsh, cod liver oil and fortiﬁed
foods such as dairy products, margarine, cereals and some juice
products as well as in supplements. Vitamin D2 which is produced
from its precursor ergosterol and is found in yeast and mushrooms
exposed to ultraviolet radiation. It is also used in the fortiﬁcation of
some foods and in supplements and pharmaceutical vitamin D
preparations [2]. Both vitamin D2 and vitamin D3 (D represents
either) when ingested is incorporated into the chylomicrons and is
transported from the lymphatic system into the venous blood
stream for transport to the liver. In the liver, vitamin D is converted
to its major circulating form 25-hydroxyvitamin D [25(OH)D].
25(OH)D bound to its vitamin D binding protein (DBP) is trans-
ported to the kidneys where it is converted to its active form, 1,25-
dihydroxyvitamin D [1,25(OH)2D].1,25(OH)2D exits the kidneys and
is transported to the small intestine where it interacts with its
nuclear vitamin D receptor (VDR) and the retinoic acid X receptor
(RxR) to form a heterodimer complex. This complex interacts with
speciﬁc vitamin D responsive elements to initiate or inhibit tran-
scription of genes that control intestinal calcium absorption (Fig. 1).
1,25(OH)2D also travels to the skeletonwhere it binds to the VDR in
osteoblasts to induce RANK ligand (RANKL). RANKL interacts with
its receptor on monocytes resulting in the transformation into bone
resorbing osteoclasts [2,3] (Fig. 1). Thus the major function of
vitamin D is to maintain calcium homeostasis by increasing intes-
tinal calcium transport. When there is inadequate calciumse.
Figure 1. Schematic representationof the synthesis andmetabolismof vitaminD for skeletal andnon-skeletal function. During exposure to sunlight, 7-dehydrocholesterol in the skin is
converted to previtaminD3. PrevitaminD3 immediately converts bya heat-dependent process to vitamin D3. Excessive exposure to sunlight degrades previtaminD3 and vitaminD3 into
inactive photoproducts. VitaminD2 and vitaminD3 fromdietary sources are incorporated into chylomicrons, transportedby the lymphatic system into the venous circulation. VitaminD
(D represents D2 or D3) made in the skin or ingested in the diet can be stored in and then released from fat cells. Vitamin D in the circulation is bound to the vitamin D-binding
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skeleton (Fig. 1).Figure 2. Showing the relation of total cancer mortality rates to Smith’s Solar Radia-
tion Index in the American states, (white population only). Reproduced with
permission.Association studies linking sun exposure and vitamin D status
with cancer risk
In 1916 Hoffman [4] reported that living at higher latitudes was
associated with increased risk for mortality from cancer. He
compared cancer mortality between 1908 and 1912 and concluded
that cancer mortality increased with increasing distance from the
equator. 20 years later Peller and Stephenson [5] reported that
United States Navy personnel who principally worked outside had a
60% less likelihood of dying from cancer compared to the civilian
population who principally worked indoors. In 1941 Apperly [6]
made a similar observation when he compared cancer mortality
in Americans and Canadians who were in the agricultural business
and exposed to a lot of sunlight and observed that cancer mortality
signiﬁcantly declined for farmers who lived in the south compared
to the Northeast. Both Apperly and Peller and Stephenson [5] also
recognized that thosewhoweremost exposed to sunlight had up to
an 8 times higher risk of developing nonmelanoma skin cancer
which they noted were easy to detect and easy to treat. Apperly [6]
had suggested that by developing nonmelanoma skin cancer that
this imparted at an immunity to all cancers including thosewith the
highest mortality breast, colon and prostate cancers.
Little attention was paid to these insightful observations until
the 1980s when Garland et al. [7] reported a strong positive cor-
relation with reduced risk for colorectal cancer mortality with
increased mean daily solar radiation i.e. living at lower latitudes in
United States. This initiated an 8 year prospective case-controlled
study of adults living in Washington County, MD relating their
vitamin D status i.e. serum 25(OH)D with their risk of developing
colon cancer. They observed that for those who had at the initiation
of the trial a 25(OH)D > 20 ng/mL had a 3 fold decreased risk for
developing colon cancer [8]. Thus Garland et al. [8] made the
connection with living at higher latitudes and having less sun
exposure and less vitamin D production and was associated with a
lower blood level of 25(OH)D with increased risk for colon cancer.
Since these initial insightful observations a multitude of epide-
miologic studies have reported an association with decreased sun
exposure or lower vitamin D status with increased risk for a variety
of cancers including breast, colon, lymphoma, lung and prostate
cancers [9e11]. Grant [12] evaluated mortality due to cancer andprotein(DBP), which transports it to the liver, where vitamin D is converted by the vitamin D
of vitamin D that is used by clinicians to measure vitamin D status (although most reference la
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vitamin D receptor (VDR). The 1,25(OH)2D3-VDR complex heterodimerizes with the retinoic a
gene. The DNA bound heterodimer attracts components of the RNA polymerase II complex an
(FGF-23), andother factors caneither increaseordecrease the renalproductionof 1,25(OH)2D.1
of parathyroid hormone (PTH) in the parathyroid glands. 1,25(OH)2D increases the expression
water-soluble, biologically inactive calcitroic acid,which is excreted in the bile.1,25(OH)2D enh
the epithelial calcium channel (ECaC) and the calbindin 9K (calcium-binding protein, CaBP).1,2
of the receptor activator of the NF-kB ligand (RANKL). Its receptor RANK on the preosteoclast b
osteoclast removes calciumandphosphorus fromthebone tomaintain blood calciumandphos
skeleton. Autocrine metabolism of 25(OH)D; when a macrophage or monocyte is stimulated
tuberculosis or its lipopolysaccharide, the signal up-regulates the expression of VDR and 1-O
convert 25(OH)D to1,25(OH)2D inmitochondria.1,25(OH)2D travels to thenucleus,where it inc
inducing the destruction of infectious agents such asM. tuberculosis. It is also likely that the 1,
lymphocytes,which regulate cytokine synthesis, andactivatedB lymphocytes,which regulate i
many common cancers is reduced. It is believed that the local production of 1,25(OH)2D in th
liferation, including p21 and p27, aswell as genes that inhibit angiogenesis and induce differen
proliferation and differentiation, it induces expression of the enzyme 24-OHase, which enh
produced (autocrine) 1,25(OH)2D does not enter the circulation and has no inﬂuence on calciu
1,25(OH)2D inhibits the expression and synthesis of parathyroid hormone. The 1,25(OH)2D pro
kidney and stimulate insulin secretion in the beta islet cells of the pancreas. Holick copyrightrelated it to UV exposure in both men and women. He found a
dramatic inverse relationship (Fig. 2) conﬁrming the earlier studies
of Apperly [6] and Peller and Stephenson [5]. Grant [12e14] also
reported that more than 13 cancers were reduced by adequate
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2013 Reproduced with permission.
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of inadequate exposure to solar UVB radiation. He also concluded
that approximately 50,000e63,000 Americans and 1900e25,000
British citizens died prematurely of cancer each year due to vitamin
D deﬁciency [13,14]. His conclusions are consistent with the recent
meta-analysis by Keum and Giovannucci [15] who concluded that
several lines of evidence suggests that the effects of vitamin D may
be stronger for cancer mortality than for incidence. Indeed Maalmi
and et al. [16]. reported a meta-analysis of prospective cohort
studies and concluded among colorectal cancer patients pooled
hazard ratios (95% conﬁdence intervals) comparing highest and
lowest 25(OH)D levels were 0.71 (0.55e0.91) and 0.65 (0.49e0.86)
for overall and disease-speciﬁc mortality respectively. For breast
cancer patients the corresponding pooled estimates were 0.62
(0.49e0.78) and 0.58 (0.38e0.84) respectively. It was concluded
that a 25(OH)D > 30 ng/mL was associated with this signiﬁcantly
reduced mortality in patients with colorectal and breast cancer.
Epidemiologic studies have suggested that adequate levels of
25(OH)D are critical for the prevention of various solid tumors
including ovarian, breast, colon and prostate cancers. A meta-
analysis for the US Preventative Services Task Force regarding
vitamin D supplementation concluded that each 4-ng/mL increase
in blood 25(OH)D levels was associated with a 6% reduced risk of
colorectal cancer [17]. One of the outcome measures for the large
Women’s Health Initiative Study (WHI) was evaluation for the ef-
fect of calcium and vitamin D on reducing risk for colorectal cancer.
It was concluded that there was no beneﬁt for ingesting 1000 mg of
calcium and 400 IUs of vitamin D daily regarding colon cancer risk
[18]. However womenwho had a baseline level of 25(OH)D< 12 ng/
mL and who took the calcium and vitamin D supplement had a
253% increased risk of developing colorectal cancer compared to
womenwho took the same amount of vitamin D3 and calcium for 7
years and had a baseline 25(OH)D level of at least 24 ng/mL [19].
Furthermore a reanalysis of the WHI revealed that 15,646 women
(43%) who were not taking personal calcium or vitamin D supple-
ments at the initiation of the trial and who are now randomized to
be taking the calcium and vitamin D supplement had a signiﬁcantly
decreased risk of colorectal cancer by 17% and total breast and
invasive breast cancers by 14% and 20% [20]. In a randomized
controlled trial of osteoporotic women who received 1500 mg of
elemental calcium and 1100 IUs of vitamin D3 daily for 4 years had a
reduced risk of developing all cancers by 60%. The study was
strengthened by a meta-analysis whereby if it was assumed that
during the ﬁrst year some of the women may have already had a
developing cancer when the ﬁrst year was removed from the
analysis and even stronger 77% reduction in all cancers was
observed [21].
The associations with reduced exposure to solar ultraviolet ra-
diation with increased risk for cancer has been observed in more
than 100 countries including Australia, Japan, Chinawhere it is been
reported that there is an inverse relationship with solar UVB
exposure for 15 types of cancer including breast, cervical, colon,
endometrial, esophageal, gastric, lung, ovarian, bladder and non-
Hodgkin’s lymphoma [3,10,22,23]. Luscombe et al. [24] reported
that men in Finland who worked outdoors had a 3 year hiatus
before developing prostate cancer compared to indoor workers.
Adults who developed lymphoma had decreased risk for mortality
if they had more sun exposure as a teenager [25]. The concept that
sensible sun exposure during teenage and young adult years is
supported by the study of Knight et al. [26] who reported that
women who had the most sun exposure from ages 10e19 years
reduced risk of developing breast cancer by more than 60%
compared to those with the least sun exposure. This beneﬁt was
lost in women who had increased their sun exposure after the age
of 40 years.The vitamin D, sunlight and cancer conundrum
It is well documented that 1,25(OH)2D3 is one of the most potent
hormones in decreasing cellular proliferation and inducing termi-
nal differentiation in a variety of normal and malignant cells that
contain a VDR [1e3,27]. Although the exact mechanism by which
1,25(OH)2D3 is able to regulate cellular proliferation and differen-
tiation a large number of genes that control proliferation, differ-
entiation, apoptosis and angiogenosis are either directly or
indirectly inﬂuenced by 1,25(OH)2D3. 1,25(OH)2D3 increased in-
hibitors and decreased activators of cyclin-cyclin-dependent kinase
complexes in addition to increasing levels of cyclin-dependent ki-
nase inhibitors Cip/Kip proteins P 21 and P 27. These proteins are
responsible for keeping the cell cycle in G1/S phase, preventing
DNA synthesis and therefore cellular growth [1e3,28e32]. Other
strategies that 1,25(OH)2D3 uses to help reduce the development of
malignancy is to induce apoptosis and to reduce the blood supply to
the developing tumor [28e34] (Fig. 3). A recent study in healthy
adults who receives vitamin D supplementation for 4 months re-
ported that 291 genes were signiﬁcantly inﬂuenced many of which
control cellular proliferation, maturation, immune function as well
as antioxidant activity all that are related to the potential for
regulating cellular growth and reducing risk for malignancy [35]
(Fig. 3).
In the 1980s and 90s numerous publications reported that
1,25(OH)2D3 was a potent inhibitor of a wide variety of cultured
cancer cells including breast, colon and prostate cell lines [1,3,31].
However clinical studies with 1,25(OH)2D3 for treating preleukemia
and prostate cancer were unsuccessful in part due to the observed
toxicity i.e. hypercalcemia associated with the hormone [36e37].
However the observation that topically applied or orally adminis-
tered 1,25(OH)2D3 was effective for the treatment of the non-
malignant hyperproliferative skin disorder psoriasis demonstrated
that this hormone did in fact have potent antiproliferative in pro-
differentiating properties that could be used clinically [3,38].
There is signiﬁcant scientiﬁc evidence to suggest that mainte-
nance of adequate vitamin D status is important for the prevention
of a wide variety of deadly cancers [9e17,39e42]. Woo et al. [43]
reported that men with metastatic prostate cancer who received
2000 IUs of vitamin D3 daily had as much is a 50% reduction in
prostate-speciﬁc antigen levels after 21 months. Tangpricha et al.
[44] observed that mice who were vitamin D deﬁcient and injected
with mouse colon cancer cells (MC-26) had 60% greater tumor
growth compared to the mice who received the same colon cancer
cells but who were vitamin D sufﬁcient throughout the study.
Similarly a study in immunodeﬁcient mice revealed that main-
taining a normal vitamin D status reduced the growth of a human
androgen insensitive prostate cancer (DU-145) [45].
Based on all the evidence it was concluded that the most likely
explanation for why improvement in vitamin D status reduced risk
of deadly cancers was because the increased circulating concen-
trations of 25(OH)D could be converted in the kidneys to increased
amounts of 1,25(OH)2D which in turn would be released back into
the circulation to provide its anti-tumor potential to any cell that
was prone to developing a malignancy. However because
1,25(OH)2D is such a potent hormone for regulating calcium ho-
meostasis if there was a signiﬁcant increase in the circulating level
of this hormone it would likely lead to toxicity including hyper-
calcemia, hyperphosphatemia, soft tissue calciﬁcation, neph-
rocalcinosis and ultimately death [3]. In fact the production of
1,25(OH)2D is tightly regulated in the kidneys by a variety of factors
including parathyroid hormone, calcium, phosphate and ﬁbroblast
growth factor 23 [2,3] (Fig. 1).
Herein was the conundrum. The epidemiologic, association
studies and randomized controlled trials demonstrated that
Figure 3. Biological functions for genes whose expression levels were altered after 2 months of vitamin D3 supplementation. After receiving vitamin D3 supplementation we
identiﬁed 291 genes whose expression was signiﬁcantly decreased or increased. Some of these genes inﬂuence several pathways that are involved in response to stress and DNA
repair, DNA replication, immune regulation, epigenetic modiﬁcation, transcriptional regulation and other biological functions. In addition vitamin D3 supplementation inﬂuenced
the expression of Y RNA and CETN3 that are involved in DNA repair in response to UVR exposure. Holick copyright 2013 reproduced with permission.
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deadly cancers. However, the kidneys were not producing more
1,25(OH)2D in response to higher circulating levels of 25(OH)D;
how was vitamin D having its effect? It had been previously re-
ported in the 1980s by Bikle et al. [46] that cultured human kera-
tinocytes were capable of converting 25(OH)D to 1,25(OH)2D3. It
was also reported that activated macrophages were also able to
locally produce 1,25(OH)2D3 which was responsible for the induc-
tion of cathelicidin a defensen protein that helps to lyse infective
agents engulfed by the macrophage [47]. However these observa-
tions although interesting did not seem to have any physiologic
signiﬁcance for cancer reduction until Schwartz et al. [48] reported
that normal human prostate cells also had capacity to convert
25(OH)D to 1,25(OH)2D. This observationwas conﬁrmed in a variety
of normal and malignant cell lines including those of breast, colon,
lung and melanocytes [47,48]. Based on these observations it wasconcluded that the likely explanation for why improvement in
vitamin D status was associated with reduced risk for malignancies
was due to increased circulating 25(OH)D which could enter cells
throughout the body and be converted to 1,25(OH)2D. 1,25(OH)2D
in turn controlled wide variety of genes many of which maintains
cellular health and reduced risk for malignant transformation [1e3,
28, 48, 49]. Thus vitamin D has 2 functions the ﬁrst and foremost an
endocrine function to maintain calcium homeostasis which is
critically important for not only skeletal health but for a variety of
metabolic processes (Fig. 1). The second and equally important
function is for vitamin D to function in an autocrine/paracrine
function whereby 25(OH)D is converted to 1,25(OH)2D in non-
calcium regulating cells. Once formed this hormone not only
helps to regulate cellular growth and a variety of other physiologic
functions but also induces the 25-hydroxyvitamin D-24 hydroxy-
lase (CYP24A1) [27]. This enzyme rapidly destroys 1,25(OH)2D into
M.F. Holick / Journal of Clinical & Translational Endocrinology 1 (2014) 179e186184a water-soluble calcitroic acid thus preventing this calcium active
hormone from entering into the circulation to have any inﬂuence
on calcium metabolism potentially causing toxicity [1e3] (Fig. 1).The importance of maintaining a healthy vitamin D status to
reduce risk of cancer
To date that has been very disappointing that neither
1,25(OH)2D3 or its active analogs have been proven to be effective in
the treatment of any cancer. There are likely several reasons for this
separate from the potential calcemic toxicity associated with
1,25(OH)2D3 and its active analogs. The simplest strategy is for a cell
that is malignant to markedly increase the expression of CYP24A1
which would rapidly destroy any 1,25(OH)2D3 that enters its
domain preventing it from docking in the nucleus to regulate genes
to control and destroy the malignant cell. Human prostate cancer
cells have been reported to have robust expression of this
1,25(OH)2D3 destructive enzyme [50].
Another clever strategy that malignant cells have developed to
mitigate 1,25(OH)2D3’s antitumor activity is to express the tran-
scription factor SNAIL [51]. This transcription factor is a zinc-ﬁnger
transcription factor that is involved in cell movement and exists in
both invertebrates andvertebrates. Theoverexpressionof thisgene in
the human colon cancer cell line (SW 480-ADH) resulted in
decreasing the expression of VDR thus preventing 1,25(OH)2D3 from
docking with its nuclear receptor. The over expression of SNAIL 1
induced epithelial-to-mesenchymal transition and also inhibited
E-cadherin which is important for cellular adhesion and differentia-
tion [51]. It was concluded that the ratio of VDR and SNAIL expression
in cells may be critical for E-cadherin expression which ultimately
inﬂuences cellular growth and thus colon cancer progression [51].Figure 4. Vitamin D intakes recommended by the Institute of Medicine and the Endocrine Pr
RDA ¼ recommended dietary allowance; SE ¼ standard error; UL ¼ tolerableupper intake lThus based on the autocrine/paracrine hypothesis, the ability of
many cells and organs not related to calciummetabolism being able
to locally produce 1,25(OH)2D3 is the impetus for increasing
circulating concentrations of 25(OH)D in order to reduce risk of
developing deadly cancers and the mortality associated with them.Approaches for raising blood levels of 25-hydroxyvitamin D
The Institute of Medicine (IOM) and the Endocrine Society have
both concluded that vitamin D deﬁciency should be deﬁned as a
serum 25(OH)D > 20 ng/mL [52] (Fig. 4). The IOM suggests that a
25(OH)D> 20 ng/mL is all that is required to maximize bone health
and they ignored the association studies concluding that there is no
beneﬁt of improving vitamin D status for other health outcomes
measures including reducing risk of cancer and cancer mortality
[52]. The Endocrine Society concluded based on all of the available
literature that a minimum serum level of 25(OH)D to maximize
bone health was 30 ng/mL [53]. Furthermore, the Endocrine Society
guidelines committee reviewed many of the epidemiologic studies
and concluded that there may be additional health beneﬁts that
require further investigation including reducing risk of cancers. To
achieve a blood level of at least 20 ng/mL the IOM recommended
400 IUs daily for children under one year of age, 600 IUs daily for
children one year and older and all adults up to the age of 70 years
and 800 IUs daily for adults over the age of 70. The Endocrine So-
ciety recommends children under one year of age require 400e
1000 IUs daily, children one year and older 600e1000 IUs daily and
all adults 1500e2000 IUs daily to sustain a circulating serum level
of 25(OH)D > 30 ng/mL (Fig. 4). They also recognized that obese
children and adults required 2e3 times more vitamin D to treat and
prevent vitamin D deﬁciency. To treat vitamin D deﬁciency variousactice Guidelines Committee. 25(OH) D ¼ 25-hydroxyvitamin D; AI ¼ adequate intake;
evel. Copyright Holick 2013, reproduced with permission.
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of vitamin D2 (the pharmaceutical form of vitamin D available in
United States) once a week for 8 weeks which is equivalent to
ingesting approximately 6000 IUs daily which can be equally
effective. To prevent recurrence it was recommended that 50,000
IUs of vitamin D2 once every 2 weeks which is equivalent to
approximately 3000 IUs daily is effective [54]. This strategy has
been successfully employed for up to 6 years without any untoward
toxicity [55]. Additional sources of vitamin D which can be variable
can be obtained from dietary sources and sensible sun exposure.
The use of the mobile phone app Dminder.info provides guidelines
anywhere on the globe at any time of the year for how much sun
exposure is required to make sufﬁcient vitamin Dwhile at the same
time alerting the user after the sensible sun exposure to either wear
sun protection or get out of the sun to prevent the damaging effects
from excessive exposure to sunlight.
Vitamin D toxicity
Vitamin D toxicity is extremely uncommon. Studies have shown
in adults that 10,000 IUs daily for at least 5 months did not cause
any toxicity [56]. Even in pregnant women who talk 4000 IUs daily
throughout her pregnancy raise her blood levels of 25(OH)D to
approximately 60 ng/mL without any evidence of toxicity [57].
Vitamin D intoxication which is associated with hypercalcemia
hypercalciuria hypophosphatemia soft tissue calciﬁcation and
nephrocalcinosis is usually observed when blood levels of 25(OH)
D > 300 ng/mL for a prolonged period of time [2].
There are however are a few exceptions. Patients with granu-
lomatous disorders such as sarcoidosis the to be more careful about
her vitamin D intake due to the extra renal production of
1,25(OH)2D.Toxicity is usually observed when blood levels of
25(OH)D greater than 30 ng/mL. Some patients with Hodgkin’s and
non-Hodgkin’s lymphoma also have invasion of macrophages into
their lymphoma. These activated macrophages like those in gran-
ulomatous disorders in the non-regulated fashion produce
1,25(OH)2D which can exit the macrophage into the circulation
causing hypercalciuria and hypercalcemia [53].
Conclusion
There are now tens of thousands of publications that suggest
that improvement in vitamin D status not only is important for
musculoskeletal health but for overall health and well-being by
reducing risk of both acute and chronic illnesses [1e3]. This is
especially true for the association of improved vitamin D status
with decreased risk for developing many cancers and cancer mor-
tality. Patients with cancer who are undergoing chemotherapy are
at especially high risk for vitamin D deﬁciency. They often are
advised to avoid all sun exposure because of photosensitivity to
their medications and they often have a lot of GI distress leading to
a decrease in nutrient intake including vitamin D. Patients on
chemotherapy often complain of muscle weakness and aches and
pains in her bones andmuscles which are classic signs for vitamin D
deﬁciency and osteomalacia. These patients should be monitored
carefully and receive appropriate treatment for the prevention and
treatment of vitamin D deﬁciency. It has been speculated that
improvement in vitamin D status may help improve cancer thera-
peutic outcomes although there are no control trials to support the
speculation. There is however no downside to increasing every-
one’s vitamin D status. There is enough ecological, association and
meta-analyses studies supporting the role of vitamin D in reducing
risk of deadly malignancies to warrant the recommendation for
everyone to improve their vitamin D status with increasing inges-
tion of foods fortiﬁed with vitamin D, obtaining sensible sunexposure when appropriate and taking a pharmaceutical or sup-
plemental form of vitamin D to maintain a circulating level of
25(OH)D of at least 30 ng/mL with a preferred range of 40e60 ng/
mL with up to 100 ng/mL being perfectly safe.
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